Surgical treatment of atypical metastasis from renal cell carcinoma (RCC) by Antonelli, A. et al.
BJUI
B J U  I N T E R N A T I O N A L
©  2 0 1 2  T H E  A U T H O R S
B J U  I N T E R N A T I O N A L  ©  2 0 1 2  B J U  I N T E R N A T I O N A L  |  doi:10.1111/j.1464-410X.2012.11271.x 1
 What ’ s known on the subject? and What does the study add? 
 The interest in metastatic renal cell carcinoma has increased in the last few years, 
mainly due to the advent of targeted therapies, but metastasectomy remains the sole 
therapy that can lead to a complete and durable regression, even if only in a minority 
of patients. The literature reports quite large series of metastasectomies for the most 
common sites of metastasis, e.g. lung, liver, bone, adrenal and brain, whereas little is 
known about the management of metastasis in  ‘ atypical ’ sites. 
 The prognosis of patients submitted to metastasectomy for a metastasis in an atypical 
site is equivalent to patients with lung metastasis. The characteristics of the primary 
tumour in these patients are not indicative, but atypical metastasis (AM) are often 
located in superfi cial sites and frequently associated with other metastases. So, 
physical examination should be included in all follow-up regimens and a complete 
re-staging should be performed after the diagnosis of an AM. 
 OBJECTIVE 
 •  To review the clinical characteristics and 
oncological results in patients submitted to 
surgical removal of metastasis from renal 
cell carcinoma (RCC) in atypical sites 
(atypical metastasis  [ AM ] , i.e. metastasis in 
sites other than the chest, liver, bone, 
adrenal, brain, kidney, and lymph nodes), 
compared with patients submitted to 
metastasectomy due to a lung metastasis 
(LM). 
 PATIENTS AND METHODS 
 •  From an institutional database of  ≈ 1800 
patients surgically treated for a RCC, we 
retrospectively identifi ed 37 cases that had 
undergone metastasectomy for AM and 57 
operated for LM. 
 •  Clinicopathological features of the 
primary RCC and metastasis, and cancer-
specifi c survival (CSS) computed from the 
time of metastasectomy of patients with 
AM and LM, were compared. 
 •  A univariate and multivariable analysis 
applying a Cox regression model was used 
to evaluate CSS. 
 RESULTS 
 •  The patients with AM and LM were 
followed for an average of 40.8 and 50.7 
months from metastasectomy, respectively 
( P  = 0.372). 
 •  There were no signifi cant differences in 
the characteristics of the primary tumour 
between patients with AM and LM. 
 •  In the cases with AM and LM the 
diagnosis was simultaneous with that 
of the primary tumour in 32.4% and 
24.6%, ( P  = 0.40) respectively, and, 
when metachronous, occurred at an 
average delay of 53.4 and 44.3 months 
( P  = 0.370). 
 •  More frequently in the cases with AM 
other metastases had been diagnosed in 
the previous medical history (35.2 vs 8.8%, 
 P  = 0.001) or simultaneously (48.6 vs 8.8%, 
 P  = 0.001). 
 •  CSS from metastasectomy was affected 
by the synchronicity in diagnosis between 
metastasis and primary tumour, and by the 
simultaneous presence of other metastases, 
while the type of metastasis (AM vs LM) 
did not affect CSS. In fact, metastasectomy 
in AM was as effective as in LM. 
 CONCLUSION 
 •  AM are an exceptional presentation of 
metastatic RCC, but the role of surgery is 
similar to that of pulmonary metastasis. In 
these cases, metastasectomy is accepted as 
possible care, and in AM the CSS after 
metastasectomy is similar. 
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 INTRODUCTION 
 Despite the increase in initial diagnoses 
from the widespread use of ultrasonography 
and CT, RCC remains the urological tumour 
with the highest mortality rate  [ 1 ] 
due to a signifi cant proportion (up to 
30%) of patients with metastasis at 
diagnosis or discovered during follow-up 
 [ 2 – 5 ] . 
 Although the systemic spread of a 
metastatic tumour excludes a rationale for 
local treatment, e.g. metastasectomy, this is 
actually a feasible option for RCC  [ 6,7 ] . In 
fact, despite not being supported by a high 
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level of evidence, over time, this approach 
has obtained wide consensus both due to 
the fact that in some cases it allows a 
prolonged survival and clinical regression of 
the disease, and because there is a lack of 
more effective therapeutic alternatives. Even 
targeted therapies that have recently been 
introduced into clinical practice, while 
leading to a signifi cant increase in 
survival compared with previous therapies 
 [ 6,8 – 10 ] , have not replaced the use of 
metastasectomy due to their limited ability 
for complete regression of the disease and 
the need to extend treatment, and the 
related side -effects, for an unlimited period 
 [ 6,11 – 13 ] . 
 There are published reports on the results 
of metastasectomy in the most common 
sites of RCC metastasis (lung, bone, liver, 
brain and adrenal)  [ 14,15 ] . However this 
tumour can, even though unusual, spread 
to any organ and only single case reports 
describe metastasectomies in  ‘ atypical ’ 
sites. 
 The present study aimed to assess the 
clinical characteristics and oncological 
outcome of surgical removal of metastases 
occurring in atypical sites by retrospectively 
reviewing our institutional experience. 
 PATIENTS AND METHODS 
 Since 1983 our institute has been 
prospectively compiling a database, which 
includes the clinical, surgical and follow-up 
data of  ≈ 1800 patients who have undergone 
surgery for RCC. Data were collected after 
receiving written consent from every patient 
(as required by Italian law) and under the 
authorisation of the local Ethics Committee. 
The histological specimens were evaluated 
by two skilled uro-pathologists; staging was 
adapted to the TNM 2002 system  [ 16 ] ; 
assignment of the histological subtype and 
grading followed the WHO  [ 17 ] and 
Fuhrman ’ classifi cation  [ 18 ] . For all patients 
staging included abdominal CT or MRI and a 
chest X-ray; in the absence of specifi c 
symptoms, a chest CT and a bone scan were 
indicated in cases of tumours with a clinical 
staging above second and a brain CT for 
fourth stage tumours. All patients were 
followed in a dedicated oncological 
ambulatory unit with physical examination, 
blood chemistry analysis and studies of the 
abdomen (ultrasonography or CT) and chest 
(X-ray or CT), in addition to additional tests 
in cases of specifi c clinical doubt; upon 
discovery of metastasis, total-body 
re-staging was always performed. A 
metastasectomy was proposed in patients 
with good performance status and 
resectable lesions, preferably if localised 
in a single organ or, when multiple, if the 
patient could be considered a suitable 
candidate for multiple metastasectomies or 
complementary medical treatment. 
 To date, 349 metastasectomies have been 
performed in 242 patients. 
 For this work, we selected a specifi c 
population: patients that had undergone 
surgical removal of an  ‘ atypical ’ metastasis 
(AM), defi ned as a metastasis that is 
localised in a site other than thoracic 
(pulmonary, pleural or mediastinal), skeletal, 
hepatic, adrenal or encephalic were reviewed 
for this study; direct invasion of organs by 
the tumour (stage pT4), bilateral renal 
tumours and lymph node metastases were 
excluded. 
 A comparison group was formed of patients 
that had undergone metastasectomy for a 
pulmonary metastasis or lung metastasis 
(LM), considered to be the most typical site 
for RCC metastasization. 
 Patients with AM or LM that was not 
treated surgically and those with associated 
metastases that had not undergone curative 
treatment (surgery, radiation therapy or 
medical treatment) were excluded. 
 Continuous variables were reported as mean 
( SD ) or median and interquartile range. The 
Student ’ s  t -test, the Mann – Whitney  U -test, 
Fisher ’ s exact test and the Pearson chi-
square test were used to compare 
continuous and categorical variables, as 
appropriate. 
 The Kaplan – Meier method was used to 
calculate survival functions, and differences 
were assessed with the log-rank statistic. 
Cancer-specifi c survival (CSS) was computed 
from the date of metastasectomy to the last 
available control, censoring the cases 
deceased from RCC. Univariable and 
multivariable Cox regression models 
addressed time to cancer-specifi c mortality 
after metastasectomy. Statistical signifi cance 
was set at  P  < 0.05. All reported  P -values 
are two sided. 
 RESULTS 
 In 1785 patients with RCC, 37 patients that 
underwent a metastasectomy for AM 
(incidence 1.88%, 22 men, 15 women, mean 
 [ SD ] age at diagnosis of the primary tumour 
59.1  [ 17.5 ] years;  Table  1 ) and 57 that 
underwent a metastasectomy for LM (40 
men, 17 women, mean age 60.9  [ 13.2 ] years) 
were identifi ed according to inclusion 
criteria and followed, respectively, for a 
mean ( SD ) period of 76.8 (11.4) and 84.0 (8.2) 
months from diagnosis of the primary 
tumour ( P  = 0.601) and of 40.8 (9.6) and 
50.7 (6.3) months from metastasectomy 
( P  = 0.372). In all, 36 patients with a 
diagnosis of AM that were not treated 
surgically were excluded. 
 Table  2 summarises the comparison of the 
characteristics of the primary RCC in 
patients with AM and LM, while noting in 
the former a larger proportion of non-clear 
cell tumours and with lymph node 
involvement. 
 Presentation of the AM and the LM was 
synchronous with the diagnosis of the 
primary RCC in 12/37 (32.4%) and in 14/57 
patients (24.6%), respectively ( P  = 0.40), 
while in the remaining cases it occurred at a 
mean ( SD ) latency of 53.4 (41.3) and 44.3 
(55.7) months, respectively ( P  = 0.370). 
 During the previous medical history, a 
metastasis in another organ was detected in 
13/37 (35.1%) and 5/57 patients (8.8%) with 
AM and LM, respectively, while this was 
simultaneously present at diagnosis of AM 
or LM in 18/37 (48.6%) and 5/57 (8.8%) 
 TABLE  1  Sites of AM 













S U R G I C A L  T R E A T M E N T  O F  A T Y P I C A L  R C C  M E T A S T A S E S 
©  2 0 1 2  T H E  A U T H O R S
B J U  I N T E R N A T I O N A L  ©  2 0 1 2  B J U  I N T E R N A T I O N A L  3
negative impact were the synchronous 
presentation of metastasis with the primary 
tumour ( Fig.  1 ,  P  = 0.014) and the 
simultaneous presence of multiple 
metastases ( Fig.  2 ,  P  = 0.03), while atypical 
localisation compared with pulmonary 
localisation did not have any impact ( Fig.  3 , 
log-rank test  P  = 0.626). 
 DISCUSSION 
 Despite the progressive increase of initial 
diagnosis, the mortality rate for RCC has not 
decreased in parallel  [ 1 – 6 ] , both due to the 
probable overtreatment of small and 
biologically indolent masses, as well as the 
still signifi cant proportion of masses that 
are highly aggressive and have the ability to 
metastasise at diagnosis or after radical 
surgical treatment of the primary tumour 
 [ 1 – 6 ] . 
 At present metastasectomy has gained a 
wide consensus because of the possibility of 
extending survival, even if it lacks a solid 
 TABLE  2  Features of primary RCC in patients with AM and LM 
Variable AM LM  P 
Symptomatic at diagnosis,  n / N (%) 25/37 (67.56) 37/57 (64.91) 0.827
Mean ( SD ) diameter, cm 8.9 (3.4) 7.9 (3.0) 0.128
Clear cell histology,  n / N (%) 33/37 (89.2) 57/57 (100) 0.022
Extracapsular,  n / N (%) 15/37 (40.54) 26/57 (45.61) 0.675
Venous invasion, % 32.4 25.0 0.43
pN + , % 10.8 1.8 0.059
G3 – G4, % 70.3 64.2 0.51
Multifocality, % 8.1 5.3 0.54
 TABLE  3  Analysis of CSS from metastasectomy 
Factor
Univariable analysis Multivariable analysis
 P HR (95% CI)  P HR (95% CI)
Primary RCC Clear cell hystology 0.434 1.607 (0.490 – 5.273)  –  – 
Diameter 0.157 1.067 (0.975 – 1.167)  –  – 
Lymph nodal invasion (Nx/pN0 vs pN + ) 0.218 2.115 (0.643 – 6.960)  –  – 
Grading (G1 – 2 vs G3 – 4) 0.215 0.643 (0.320 – 1.292)  –  – 
Metastasis AM vs LM 0.627 1.183 (0.600 – 2.333)  –  – 
Synchronous vs metachronous 0.017 2.287 (1.157 – 4.521) 0.059 1.969 (0.976 – 3.974)
Previous other metastasis 0.981 0.990 (0.411 – 2.381)  –  – 
Single vs multiple 0.005 3.268 (1.417 – 7.539) 0.020 2.770 (1.172 – 6.549)
Metastasectomy only vs metastasectomy  + medical therapy 0.243 2.020 (0.620 – 6.582)  –  – 
 FIG.  1.  Kaplan – Mayer curves estimating CSS in 
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 FIG.  3.  Kaplan – Mayer curve estimating CSS in 
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( P  = 0.001). In addition to metastasectomy 
12 patients, 5/37 with AM (13.5%) and 7/57 
with LM (12.3%) underwent medical 
treatment. 
 Currently, eight patients with AM at an 
average of 69 months from metastasectomy 
and 20 patients with LM at an average of 80 
months from metastasectomy are alive and 
have no evidence of disease; three patients 
with AM at 114 months from 
metastasectomy and one with LM at 81 
months from metastasectomy died from 
causes unrelated to RCC, while 26 patients 
with AM at 30 months and 36 with LM at 
33.5 months from metastasectomy are alive, 
in progression, or have died from the 
disease. 
 Analysis of CSS, calculated from the time of 
metastasectomy ( Table  3 ) showed that the 
factors with a statistically signifi cant 
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biological rationale to support it and has 
low levels of evidence (3) and grades of 
recommendation (B). Furthermore, selection 
of the ideal candidate for metastasectomy is 
still poorly defi ned and is generally reserved 
for patients with a good performance status 
and lesions that are technically resectable 
 [ 6 ] . Thus, metastasectomy was mainly 
supported by the lack of effective 
immunotherapy  [ 19 ] . Now, in the 
contemporary era of targeted therapies, the 
need to extend treatment indefi nitely, with 
the associated side-effects and economic 
costs, and the extremely low rate of 
complete regression  [ 20 ] can still justify the 
use of metastasectomy. This type of surgery 
is generally burdened by a low rate of 
morbidity and is not technically complex. 
 RCC can metastasise to virtually any 
location, but it commonly spreads to the 
lung, bone, liver, brain and adrenal gland. 
Therefore, the literature reports clinical 
studies of metastasectomy performed in 
these sites, with a fair number,  ≈ 200 cases, 
of these being in the lung  [ 21 – 30 ] . 
 In contrast, publications on the management 
and surgical treatment of AM sites are few, 
usually just limited to case reports, with the 
exception of a literature review on a period 
of  > 50 years, which included 321 cases of 
pancreatic metastasectomies and a 
multicentre study that collated 45 thyroid 
metastasectomies from 15 German 
institutions  [ 29,30 ] . 
 The aim of the present study was to 
characterise patients that underwent 
metastasectomy for RCC metastasis 
occurring in an atypical site, defi ned as 
non-localised in the thorax, bone, liver, brain 
and adrenal. A comparison group was 
compiled of patients that had undergone 
metastasectomy for the most typical RCC 
metastasis, i.e. LM. 
 The choice of considering only patients that 
underwent metastasectomy guaranteed a 
sure histological diagnosis in all cases. 
Furthermore, a selection was therefore 
made of only those patients with good 
performance status and lesions that were 
surgically resectable and not disseminated, 
thus making the comparison groups uniform 
for extent of the disease. 
 In our experience, AM were found in 15% of 
the cases that underwent metastasectomy 
(37/242 patients), they were located in 
different anatomical sites, and diagnosed 
either simultaneously to the primary tumour 
or after a long interval. The characteristics 
of the primary tumour in these cases did 
not prove to be signifi cantly different 
compared with those cases with LM and, 
therefore, it is not possible to provide 
indications for specifi c follow-up for the 
diagnosis of an AM. However, careful 
examination of the teguments, the neck and 
the genitals is recommended in all patients 
to allow, without additional costs, 
identifi cation of all atypical presentations 
with  ‘ superfi cial ’ localisation; abdominal 
investigations, performed as routine, would 
allow for diagnosis of the remaining AM. 
 In particular, the cases with AM presented 
more frequently than other metastasis, 
either simultaneously or occurring during 
their previous clinical history (25/37  [ 67.6% ] 
vs 9/57  [ 15.8% ] ), therefore, once an AM is 
diagnosed, a full re-staging is mandatory. 
 The experience reported in the present study 
confi rms that metastasectomy is a valid 
therapeutic option in metastatic RCC: a total 
of 32/94 patients (34%) are, in fact, alive or 
deceased from causes unrelated to the RCC, 
at a considerable time after metastasectomy. 
The factors that had a signifi cantly negative 
infl uence on CSS from metastasectomy were 
the simultaneous presence of multiple 
metastases ( P  = 0.020, hazard ratio  [ HR ] 
2.770) and, to a lesser extent, the 
synchronous diagnosis of metastasis 
compared with that of the primary tumour 
( P  = 0.059, HR 1.969). In the cases where 
these two conditions were absent, the 
median estimated survival rate from 
metastasectomy was extremely satisfactory 
(104 months, 95% CI 48.9 – 160.4). The lack 
of infl uence of a medical history of previous 
metastases, confi rms the opportunity to 
repeat the metastasectomy, when possible, 
as also previously noted by van der Poel 
 et  al .  [ 28 ] . 
 The atypical localisation per se had no 
prognostic impact, with a survival rate 
comparable with cases with LM. It should be 
noted that the latter were diagnosed as 
asymptomatic in almost all cases after the 
results of routine thoracic examinations, 
while the diagnosis of AM was often 
reached due to the presence of a clinically 
signifi cant and often symptomatic lesion. 
The limited numbers do not allow for 
statistical analysis, but as with the small 
number of other reported experiences 
 [ 31,32 ] , both pancreatic and thyroid 
localisation showed better survival rates, 
with a proportion of patients with no 
evidence of disease of almost 50%, which 
could possibly indicate a  relatively low 
biological aggressiveness. 
 In the present study, there was no benefi cial 
effect from the association of medical 
therapy with metastasectomy, but this 
information should be reviewed considering 
that these therapies were mainly interleukin 
2/interferon, as the study period was largely 
before the targeted therapies era. The few 
data coming from American tertiary 
academic institutions about the role of 
metastasectomy after targeted therapy are 
encouraging, but still too preliminary to 
provide conclusive advice  [ 33 ] . 
 The present study is subject to some 
limitations. It is a retrospective analysis, 
although of a prospectively compiled 
database; it is limited numerically, single-
centred and takes place over an extended 
period: the rarity of the disease in question 
would require a multi-centre study to 
overcome these limitations. 
 In conclusion, the data from the present 
study showed that metastasectomy can be 
effective in the treatment of a metastasis 
from RCC localised in an atypical site, 
especially when there are no other 
simultaneous metastases. Nevertheless, the 
high rate of recurrences make the advent of 
an effective systemic therapy of paramount 
importance. 
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